# A Case of Tegafur-Uracil-Induced Interstitial Lung Disease Presenting as Hypersensitivity Pneumonitis

## TL;DR

A 77-year-old man developed lung disease after chemotherapy, which was linked to a specific drug combination.

## Contribution

This is the first reported case of UFT-induced interstitial lung disease presenting as hypersensitivity pneumonitis.

## Key findings

- The patient developed interstitial lung disease following UFT and leucovorin therapy.
- Chest imaging showed a hypersensitivity pneumonia pattern associated with UFT.
- Corticosteroid treatment led to rapid improvement in respiratory symptoms.

## Abstract

This report describes the case of a 77-year-old man undergoing chemotherapy for synchronous lung cancer and rectal cancer. After receiving tegafur-uracil (UFT) plus leucovorin in combination with bevacizumab for rectal cancer, he developed exertional dyspnea. Chest computed tomography revealed diffuse bilateral centrilobular nodules and ground-glass opacities, suggesting a hypersensitivity pneumonia (HP) pattern of drug-induced interstitial lung disease (DI-ILD), and he was therefore admitted for further evaluation and treatment. Bronchoalveolar lavage demonstrated an increased lymphocyte fraction with a decreased CD4/CD8 ratio, and a drug-induced lymphocyte stimulation test was positive only for UFT. Based on the clinical course and these findings, the patient was diagnosed with UFT-induced interstitial lung disease. His respiratory condition improved rapidly following corticosteroid therapy. DI-ILD associated with UFT is rare, and to the best of our knowledge, no previous reports have described an HP pattern on imaging. We therefore report this case with a review of the relevant literature.